|   别称

 

DIF; TNF-A; TNFSF2; Cachectin; Tumor Necrosis Factor Ligand Superfamily Member 2

 

 

|   TNFa 简介

 

肿瘤坏死因子α(TNF-α)由中性粒细胞、活化的淋巴细胞、巨噬细胞、NK细胞、LAK细胞、星形胶质细胞内皮细胞、平滑肌细胞和一些转化细胞产生。小鼠TNF-α以膜锚定的形式出现。自然发生的TNF-α形式是糖基化的,但非糖基化的重组TNF-α具有相当的生物活性。据报道,TNF-α的生物活性原生形式是一个三聚体。人类和鼠类的TNF-α在氨基酸水平上显示出大约79%的同源性,并且这两个物种之间有交叉反应。

 

 

|   特异性

 

可检测样本中小鼠的TNFa,且与其类似物无明显交叉反应

 

 

|   典型数据及参考曲线

 

由于实验操作条件的不同( 如操作者、移液技术、洗板技术和稳定条件等),标准曲线的OD值会有所差异。以下数据和曲线仅供参考,实验者需根据自己的实验建立标准曲线。

 

浓度(pg/mL) 80 40 20 10 5 2.5 1.25 0
OD值 2.36 1.78 1.23 0.79 0.46 0.29 0.17 0.09
校正OD值 2.27 1.69 1.14 0.7 0.37 0.2 0.08 -

 

注意:本图仅供参考,应以同次试验标准品所绘标准曲线计算标本含量。

 

 

|   重复性

 

板内变异系数小于10%,板间变异系数小于10%

 

 

|   回收率

 

在选取的健康小鼠血清、血浆中加入3个不同浓度水平的小鼠TNFa,计算回收率

 

样本类型 范围 平均回收率
血清(n=8) 84-101 96
血浆(n=8) 91-106 102

 

 

|   线性稀释

 

分别在选取的4份健康小鼠血清、血浆中加入高浓度小鼠TNFa,在标准曲线动力学范围内进行稀释,评估线性。

 

稀释比例 回收率(%) 血清 血浆
1:2 范围(%) 84-96 88-97
平均回收率(%) 90 93
1:4 范围(%) 89-104 87-108
平均回收率(%) 93 98

 

 

注:ELISA试剂盒检测范围等数据,因检测样本 的不同而调整,实际数据以随货说明书为准。

 

 

|   ELISA操作视频

 

ELISA操作视频        ELISA保存温度

 

 

|   ELISA操作前必读 / 下载

 

样本处理    血液样本    加样    温育

 

洗板    拟合曲线    常见问题    下载

 

 

|   客户发表的文献

 

 

Protective Effects of Selenium Nanoparticle-EnrichedLactococcus lactis NZ9000 against Enterotoxigenic Escherichia coli K88-Induced Intestinal Barrier Damage in Mice

Rank: IF 44

Journal: Applied and Environmental Microbiology

Year: 2021

DOI: 10.1128/AEM.01636-21

 


 

Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid

Rank: IF 28.3

Journal: Nature Microbiology

Year: 2023

DOI: 10.1038/s41564-023-01418-7

 


 

The circular RNA circINPP4B acts as a sponge of miR-30a to regulate Th17 cell differentiation during progression of experimental autoimmune encephalomyelitis

Rank: IF 24.1

Journal: Cellular & Molecular Immunology

Year: 2021

DOI: 10.1038/s41423-021-00748-y

 


 

Gastrointestinal MicroenvironmentResponsive Nanoencapsulation of Probioticsand Drugs for Synergistic Therapy ofIntestinal Diseases

Rank: IF 17.1

Journal: ACS Nano

Year: 2023

DOI: 10.1021/acsnano.3c02646

 


 

Enrichment and sensing tumor cells by embedded immunomodulatory DNA hydrogel to inhibit postoperative tumor recurrence

Rank: IF 16.6

Journal: Nature Communications

Year: 2023

DOI: 10.1038/s41467-023-40085-4

 


 

Gas therapy potentiates aggregationinduced emission luminogen-based photoimmunotherapy of poorly immunogenictumors through cGAS-STING pathwayactivation

Rank: IF 16.6

Journal: Nature Communications

Year: 2023

DOI: 10.1038/s41467-023-38601-7

 


 

Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis

Rank: IF 15.5

Journal: Microbiome

Year: 2021

DOI: 10.1186/s40168-021-01107-9

 


 

Hypoxia-responsive immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy for potentiating cancer immunotherapy

Rank: IF 15.1

Journal: Chemical Engineering Journal

Year: 2022

DOI: 10.1016/j.cej.2022.138781

 


 

Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo

Rank: IF 15.1

Journal: Advanced Science

Year: 2019

DOI: 10.1002/advs.201801423

 


 

Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-κB pathway through microbiota–gut–brain axis

Rank: IF 14.5

Journal: Acta Pharmaceutica Sinica B

Year: 2021

DOI: 10.1016/j.apsb.2021.03.020